Filing Flows › Macrogenics (MGNX) › Q4 2024
Macrogenics (MGNX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 20, 2025
Macrogenics (MGNX) reported revenue of $19.4M for the fourth quarter 2024 (Q4 2024), +81% from a year earlier and -83% from the quarter before. Operating margin was -273.0%, net loss $15.4M (79.7% of revenue).
Macrogenics, Q4 2024: revenue $19.4M (+80% year over year), operating margin -273.0%, net loss $15.4M, operating cash flow −$38.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.4M | -83% | +81% |
| Operating profit | −$52.8M | — | — |
| Net earnings | −$15.4M | — | — |
| Operating cash flow | −$38.4M | — | — |
What changed
Revenue was $19.4M in Q4 2024, up 81% year over year and down 83% from the previous quarter.
Operating costs exceeded revenue by $52.8M, an operating margin of -273.0%. Total costs grew 20% against revenue growth of 81%. The fastest-growing cost line was General & admin (+121%). The quarter ended with a net loss of $15.4M, after a profit of $56.3M the previous quarter. Non-operating items added $38.4M, -265% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$38.4M. Non-cash charges added back $2.1M of depreciation and amortization and $11.3M of share-based compensation. Working capital and other items used $36.3M. Capital expenditures of $620K exceeded it, leaving free cash flow of −$39.0M.
Questions
What was Macrogenics' revenue in the fourth quarter 2024?
Macrogenics (MGNX) reported revenue of $19.4M for the fourth quarter 2024 (Q4 2024), +81% from a year earlier and -83% from the quarter before.
Was Macrogenics profitable in the fourth quarter 2024?
Operating loss was $52.8M (-273.0% of revenue) and net loss $15.4M.
Source: Macrogenics 10-K on SEC EDGAR.